Melanoma Coverage from Every Angle
Advertisement
Advertisement

Recent News

Nivolumab and Ipilimumab in Melanoma: OpACIN Trial Follow-up
Can Second Opinions From Pathologists Improve Melanoma Diagnoses?
The Wistar Institute Awarded $12.5M Grant for Melanoma Targeted Therapies
ESMO 2019: Neoadjuvant Talimogene Laherparepvec in Advanced Resectable Melanoma
New $1M Grants for Research on Melanoma Metastasis
ESMO 2019: Cobimetinib Plus Atezolizumab Versus Pembrolizumab in BRAF V600 Wild-Type Melanoma
ESMO 2019: Update From CheckMate 238 of Nivolumab Versus Ipilimumab in Advanced Melanoma
ESMO 2019: 5-Year Survival Data on Nivolumab Plus Ipilimumab in Advanced Melanoma
Novel Vaccine for Melanoma Is Focus of Preclinical Research
Potential of Novel Combination Under Study in Metastatic Mucosal Melanoma
Cryopreserved Lifileucel in Advanced Refractory Metastatic Melanoma
Quality Care 2019: Effect of Interdisciplinary Shared Medical Appointments on Melanoma Survivors
Can Targeting Brain Pathways Inhibit Brain Metastasis in Patients With Melanoma?
Triple-Drug Therapy Under Study in BRAF-Mutant Melanoma
Does Combination Immunotherapy Improve Survival in Metastatic Uveal Melanoma?
Epacadostat With Pembrolizumab in Advanced Melanoma
Genetics + Environment: Evidence of Synergy in Increasing Skin Cancer Risk
Bempegaldesleukin With Nivolumab Granted Breakthrough Therapy Designation in Melanoma
Assessing Anti–PD-1 Therapy Efficacy After Complete Response in Melanoma
COLUMBUS Trial: Updated Outcomes With BRAF/MEK Inhibitors in Advanced Melanoma
Novel Immunotherapy Combination Active in Metastatic Melanoma
FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Melanoma
WCD 2019: Can Reflectance Confocal Microscopy Prevent Unnecessary Skin Lesion Excision?
Predicting Response to Immunotherapy in Metastatic Melanoma
ASCO 2019: Predicting Treatment Outcomes in Melanoma With Circulating Tumor DNA Kinetics
ASCO 2019: Survival Update on Dabrafenib Plus Trametinib in BRAF V600–Mutant Melanoma
Can Novel Imaging Technique Diagnose and Treat Skin Cancer Without Cutting Skin?
ASCO 2019: Continued Benefit Reported With Adjvuant Ipilimumab in Resected Melanoma
ASCO 2019: Neoadjuvant Therapy in Melanoma: Pathologic Response and Relapse
ASCO 2019: Nivolumab Plus Ipilimumab for Symptomatic Melanoma Brain Metastases
ASCO 2019: Whole-Brain Radiation vs. Observation for Melanoma Brain Metastases
EORTC Updates Sentinel Lymph Node Biopsy Protocol in Melanoma
Is BRAF V600E Mutation of Prognostic Value in Nonmetastatic Melanoma?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.